Clinical Performance of Three Commercial Molecular Diagnostic Assays for the Detection of Fluoroquinolone Resistance-Associated Mutations in Mycoplasma genitalium.
Humans
Fluoroquinolones
/ pharmacology
Anti-Bacterial Agents
/ pharmacology
Moxifloxacin
/ therapeutic use
Mycoplasma genitalium
/ genetics
Pathology, Molecular
Macrolides
/ pharmacology
Drug Resistance, Bacterial
/ genetics
Mycoplasma Infections
/ diagnosis
RNA, Ribosomal, 23S
/ genetics
DNA, Bacterial
/ genetics
Mutation
Mycoplasma genitalium
antibiotic resistance
commercial kits
detection
fluoroquinolone
Journal
Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564
Informations de publication
Date de publication:
21 12 2022
21 12 2022
Historique:
pubmed:
3
11
2022
medline:
24
12
2022
entrez:
2
11
2022
Statut:
ppublish
Résumé
The high prevalence of macrolide resistance in Mycoplasma genitalium results in an increased reliance on moxifloxacin, the second-line treatment; however, moxifloxacin resistance has also emerged. Because assays that can detect fluoroquinolone resistance-associated mutations will be useful for the management of macrolide-resistant M. genitalium infections, we evaluated the performance of three commercial assays (the Allplex MG & MoxiR Assay [Seegene], LightMix Modular parC kit [TIBMOLBIOL], and MGMO qPCR [NYtor) in comparison with
Identifiants
pubmed: 36321820
doi: 10.1128/jcm.01135-22
pmc: PMC9769504
doi:
Substances chimiques
Fluoroquinolones
0
Anti-Bacterial Agents
0
Moxifloxacin
U188XYD42P
Macrolides
0
RNA, Ribosomal, 23S
0
DNA, Bacterial
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0113522Références
J Clin Microbiol. 2021 May 19;59(6):
pubmed: 33731412
Antimicrob Agents Chemother. 2022 May 17;66(5):e0027822
pubmed: 35475636
Emerg Infect Dis. 2016 Sep;22(9):1677-9
pubmed: 27533360
J Clin Microbiol. 2019 Oct 23;57(11):
pubmed: 31434719
Lancet Infect Dis. 2020 Nov;20(11):1302-1314
pubmed: 32622378
Antimicrob Agents Chemother. 2013 Apr;57(4):1772-6
pubmed: 23357772
Int J STD AIDS. 2020 Mar;31(3):190-197
pubmed: 32000587
J Antimicrob Chemother. 2022 May 29;77(6):1592-1599
pubmed: 35352120
J Antimicrob Chemother. 2001 Nov;48(5):742-4
pubmed: 11679571
J Med Microbiol. 2021 Mar;70(3):
pubmed: 33612146
PLoS One. 2018 Jun 8;13(6):e0198355
pubmed: 29883482
Lancet Infect Dis. 2022 Sep;22(9):e267-e270
pubmed: 35325618
J Clin Microbiol. 2020 Jan 28;58(2):
pubmed: 31801835
Sex Transm Infect. 2019 Jun;95(4):237
pubmed: 31097546
Science. 1995 Oct 20;270(5235):397-403
pubmed: 7569993
Emerg Infect Dis. 2020 Feb;26(2):332-335
pubmed: 31961302
MMWR Recomm Rep. 2021 Jul 23;70(4):1-187
pubmed: 34292926
J Eur Acad Dermatol Venereol. 2022 May;36(5):641-650
pubmed: 35182080
J Clin Microbiol. 2019 Feb 27;57(3):
pubmed: 30602443
J Infect Chemother. 2022 Mar;28(3):377-383
pubmed: 34836778
Diagn Microbiol Infect Dis. 2020 Aug;97(4):115062
pubmed: 32451118
J Infect Dis. 2020 Mar 2;221(6):1017-1024
pubmed: 32031634
J Clin Microbiol. 2020 Sep 22;58(10):
pubmed: 32719034
Sex Transm Infect. 2022 Jun 16;:
pubmed: 35710533
Emerg Infect Dis. 2017 May;23(5):809-812
pubmed: 28418319
Int J STD AIDS. 2013 Oct;24(10):822-8
pubmed: 24052013
J Clin Microbiol. 2020 Feb 24;58(3):
pubmed: 31896664